NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997

Journal of Rheumatology

Volumn 25, Issue SUPPL. 51, 1998, Pages 8-16

  Singh, Gurkirpal ^a,b,c   Ramey, Dena Rosen ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARAMIS Post Mktg Survlnc Program

^c ARAMIS   (United States)

Author keywords

ARTHRITIS; GASTROINTESTINAL; NONSTEROIDAL ANTIINFLAMMATORY DRUG ADVERSE EVENTS

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; CIMETIDINE; DICLOFENAC; FAMOTIDINE; FENOPROFEN; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PREDNISONE; RANITIDINE; SALSALATE; SUCRALFATE; SULINDAC; TOLMETIN;

ABDOMINAL PAIN; AGING; ANOREXIA; CONFERENCE PAPER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEARTBURN; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VOMITING; ARTHRITIS; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL DISEASE; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; GASTROINTESTINAL DISEASES; HUMANS;

EID: 0032066149     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Fries JF, McShane DJ. ARAMIS (The American Rheumatism Association Medical Information System): A prototypical national chronic-disease data bank. West J Med 1986;145:798-804.
2. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
3. Altman R, Asch E, Bloch DA, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
4. Altman RD, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990;33:1601-10.
5. Altman RD, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14.
6. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease modifying antirheumatic drugs. Arthritis Rheum 1993;36:297-306.
7. Singh G, Fries JF, Spitz PW, Williams CA, Bloch DA. Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. Arthritis Rheum 1989;32:837-43.
8. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
9. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
10. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
11. Ramey DR, Singh GS, Fries JF. The Health Assessment Questionnaire 1995: Status and review. In: Spilker B, editor. Pharmacoeconomics and quality of life in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven; 1996:227-37.
12. Graham DY, Smith JL. Gastroduodenal complications of chronic NSAID therapy. Am J Gastroenterol 1988;83:1081-4.
13. Buchanan WW, Brooks PM. Prediction of organ system toxicity with anti-rheumatic drug therapy. In: Bellamy N, editor. Prognosis in the rheumatic diseases. Boston: Kluwer Academic Publishers; 1991:403-50.
14. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs: differences and similarities. N Engl J Med 1991;324:1716-25.
15. Hardin JG, Longenecker GL. Handbook of drug therapy in rheumatic disease. Pharmacology and clinical aspects. Boston: Little, Brown Co.; 1992.
16. Paulus HE. Nonsteroidal anti-inflammatory drugs. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB, editors. Textbook of rheumatology. Philadelphia: WB Saunders; 1989:765-91.
17. Ehsanullah RS, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297:1017-21.
18. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum H, Fries JF. Gastrointestinal tract complications of non-steroidal antiinflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study. Arch Intern Med 1996;156:1530-6.
19. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
20. Singh G, Ramey DR, Terry R, Triadafilopoulus G. NSAID-related effects on the GI tract: an ever widening spectrum [abstract]. Gastroenterol 1997;112:A292.
21. Goldenberg DL, Cohen AS. Drugs in the rheumatic diseases. New York: Grune and Stratton; 1986.
22. Caruso I, Bianchi Porro G. Gastroscopic evaluation of antiinflammatory agents. BMJ 1980;280:75-8.
23. McCarthy DM. Nonsteroidal antiinflammatory drug induced ulcers: management by traditional therapies. Gastroenterol 1989;96:662-74.
24. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993;36:447-59.
25. Gabriel SE, Campion ME, O'Fallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994;37: 333-41.
26. Paulus HE. Government affairs. FDA Arthritis Advisory Committee meeting: risks of agranulocytosis/aplastic anemic, flank pain, and adverse gastrointestinal effects with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1987;30:593-5.
27. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
28. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
29. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
30. Fries JF, Williams CA, Bloch DA, Michel BA. NSAID-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213-222.
31. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulcerations. Gut 1987;28:527-32.
32. Fries JF. NSAID gastropathy: epidemiology. J Musculoskel Med 1991;8:21-8.
33. National Center for Health Statistics: GMWKI: Total deaths for each cause by 5-year age groups: United States, 1994 (unpublished data from NCHS website data warehouse). Hyattsville, MD: Public Health Service; 1997.
34. Larkai EN, Smith JL, Lidsky MD. Gastroduodenal mucosa and dyspeptic symptoms in arthritis patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
35. Polisson R. Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Am J Med 1996;100 Suppl 2A:31S-36S.
36. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995;38:5-18.
37. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
38. Bjorkman DJ. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Am J Med 1996;101 Suppl 1A:25S-32S.
39. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995;90:206-10.
40. Greene JM, Winickoff RN. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions. Arch Intern Med 1992;152:1995-2002.
41. Hallas J, Lauritsen J, Villadsen HD, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995;438-44.
42. Hochain P, Berkelmans I, Czernichow P, et al. Which patients taking non-aspirin nonsteroidal anti-inflammatory drugs bleed? A case-control study. Eur J Gastroenterol Hepatol 1995;7:419-26.
43. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40.
44. Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of non-steroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-70.
45. Physicians' Desk Reference. Montvale, NJ: Medical Economics Company; 1996.
46. Lanza FL, Royer GL, Nelson RS, Chen TT, Seckman CE, Rack MF. A comparative endoscopie evaluation of damaging effects of nonsteroidal antiinflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol 1981;75:17-21.
47. Lanza FL, Nelson RS, Greenberg BP. Effects of fenbufen, indomethacin, naproxen and placebo on gastric mucosa of normal volunteers. Am J Med 1983;75:75-9.
48. Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal antiinflammatory agents. Am J Med 1984;77 Suppl 1a:19-24.
49. Lanza F, Rack MF, Lyn M, Wolf J, Sanda M. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol 1987;14:338-41.
50. Lanza F, Rack MF, Doucette M, Ekholm B, Goldlust B, Wilson R. An endoscopic comparison of the gastroduodenal injury seen with salsalate and naproxen. J Rheumatol 1989;16:1570-4.
51. Carson JL, Strom BL, Morse ML, et al. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med 1987;147:1054-9.
52. Fries JF, Spitz PW, Williams CA, Bloch DA, Singh G, Hubert HB. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990;33:121-30.
53. Fries JF, Williams CA, Bloch DA. The relative toxicity of non-steroidal anti-inflammatory drugs. Arthritis Rheum 1991;34:1353-60.
54. Fries JF, Ramey DR, Singh G, Morfeld D, Bloch DA, Raynauld JP. A reevaluation of aspirin therapy in rheumatoid arthritis. Arch Intern Med 1993;153:2465-71.
55. Singh G, Williams CA, Ramey DR, Fries JF. A toxicity index for comparison of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs [abstract]. Arthritis Rheum 1993;36 Suppl 9:S178.
56. Singh G, Ramey DR, Morfeld D, Fries JF. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther 1994;62:175-91.
57. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci 1989;34:424-8.
58. Oddsson E, Gudjonsson H, Thjodleifsson B. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol 1992;27:1045-8.
59. Avorn J, Solomon D, Levin R, Lo J. Epidemiologic analysis of prophylactic drug use and NSAID gastropathy [abstract]. Arthritis Rheum 1996;39 Suppl:S165.